Satyavir Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Satyavir Yadav has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Rajiv Narang
5 shared publications- Ambuj Roy
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, Delhi, India
3 shared publications Abhishek Thakur
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
2 shared publicationsAnish Kapil
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
2 shared publicationsAseem Basha
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India (Drs Suresh, Bakshi, Khan, Basha, Yadav, S. Singh, Ali, Chauhan, and Roy)
2 shared publicationsBhawna Rao
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in Indian Heart Journal
Thromboelastography-based assessment of thrombus burden in ST-elevation myocardial infarction
- 2 September 2026
- Published by Elsevier in Indian Heart Journal
Open AccessThromboelastography-based assessment of thrombus burden in ST-elevation myocardial infarction
- Open Access
- 30 July 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (1) , 53-56
Circumaortic Configuration of the Left Coronary Arteries
Coronary artery anomalies can be divided into anomalies of origin, course, or terminations of any of the epicardial coronary arteries. Coexistence of anomalous origin of the left circumflex artery with retroaortic course and anomalous origin of left anterior descending artery arising from the right coronary sinus with interarterial course is an exceedingly rare anatomical configuration. In the presence of this anomaly, conventional catheter angiography is challenging due to technical reasons and may lead to an inadvertent misdiagnosis of significant stenosis or occlusion of the coronary artery. This case highlights the importance of coronary computed tomography angiography in identifying a rare coronary artery anomaly and providing guidance for future endovascular or surgical procedures.
- 30 July 2026
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 22 (1) , 53-56
Open AccessCircumaortic Configuration of the Left Coronary Arteries
Coronary artery anomalies can be divided into anomalies of origin, course, or terminations of any of the epicardial coronary arteries. Coexistence of anomalous origin of the left circumflex artery with retroaortic course and anomalous origin of left anterior descending artery arising from the right coronary sinus with interarterial course is an exceedingly rare anatomical configuration. In the presence of this anomaly, conventional catheter angiography is challenging due to technical reasons and may lead to an inadvertent misdiagnosis of significant stenosis or occlusion of the coronary artery. This case highlights the importance of coronary computed tomography angiography in identifying a rare coronary artery anomaly and providing guidance for future endovascular or surgical procedures.
- Open Access
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Metoprolol therapy in patients with Eisenmenger Syndrome (MINES) study. A single-center, double-blinded, randomized, placebo-controlled trial
BackgroundBeta-blockers may be useful in the prevention of progressive heart failure and sudden death in Eisenmenger syndrome (ES). The guidelines advise against their use due to concerns over negative inotropic effects despite limited evidence of potential benefits.MethodsIn this single-center, double-blind, randomized, placebo-controlled trial, patients aged >12–60 years with ES, oxygen saturation ≤92%, and WHO functional class II/III were randomized 1:1 to metoprolol succinate (starting 25 mg daily, uptitrated to 50 mg daily) or a matching placebo for 16 weeks. The primary endpoint was the change in 6MWD from baseline to week 16. Secondary endpoints included changes in oxygen saturation, NT-proBNP, TAPSE, and clinical composite endpoint.ResultsSixty patients (mean age ~26 Yrs; 58.3% female) were randomized to metoprolol and a matched placebo group (30 per group). In the intention-to-treat analysis, the 6MWD improved by 4.9 m in the metoprolol group and 6.0 m in the placebo group (difference –1.1 m; 95% CI –17.0 to 14.8; p = 0.89). No significant differences occurred in oxygen saturation (–0.06%; 95% Cl -0.62 to 0.72; p = 0.87), TAPSE (0.05 mm; 95% Cl -0.88 to 0.75; p = 0.88), or NT-proBNP (37% increase versus 13% reduction; p = 0.06). The clinical composite occurred in 7/21 (33.3%) metoprolol patients versus 1/23 (4.3%) placebo patients (p = 0.048), driven by worsening heart failure in 5 metoprolol patients.ConclusionsMetoprolol succinate did not improve exercise capacity in ES and was associated with increased clinical worsening. Routine beta-blocker use is not recommended in Eisenmenger syndrome.
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMetoprolol therapy in patients with Eisenmenger Syndrome (MINES) study. A single-center, double-blinded, randomized, placebo-controlled trial
BackgroundBeta-blockers may be useful in the prevention of progressive heart failure and sudden death in Eisenmenger syndrome (ES). The guidelines advise against their use due to concerns over negative inotropic effects despite limited evidence of potential benefits.MethodsIn this single-center, double-blind, randomized, placebo-controlled trial, patients aged >12–60 years with ES, oxygen saturation ≤92%, and WHO functional class II/III were randomized 1:1 to metoprolol succinate (starting 25 mg daily, uptitrated to 50 mg daily) or a matching placebo for 16 weeks. The primary endpoint was the change in 6MWD from baseline to week 16. Secondary endpoints included changes in oxygen saturation, NT-proBNP, TAPSE, and clinical composite endpoint.ResultsSixty patients (mean age ~26 Yrs; 58.3% female) were randomized to metoprolol and a matched placebo group (30 per group). In the intention-to-treat analysis, the 6MWD improved by 4.9 m in the metoprolol group and 6.0 m in the placebo group (difference –1.1 m; 95% CI –17.0 to 14.8; p = 0.89). No significant differences occurred in oxygen saturation (–0.06%; 95% Cl -0.62 to 0.72; p = 0.87), TAPSE (0.05 mm; 95% Cl -0.88 to 0.75; p = 0.88), or NT-proBNP (37% increase versus 13% reduction; p = 0.06). The clinical composite occurred in 7/21 (33.3%) metoprolol patients versus 1/23 (4.3%) placebo patients (p = 0.048), driven by worsening heart failure in 5 metoprolol patients.ConclusionsMetoprolol succinate did not improve exercise capacity in ES and was associated with increased clinical worsening. Routine beta-blocker use is not recommended in Eisenmenger syndrome.
- Open Access
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Metoprolol therapy in patients with Eisenmenger Syndrome (MINES) study. A single-center, double-blinded, randomized, placebo-controlled trial
BackgroundBeta-blockers may be useful in the prevention of progressive heart failure and sudden death in Eisenmenger syndrome (ES). The guidelines advise against their use due to concerns over negative inotropic effects despite limited evidence of potential benefits.MethodsIn this single-center, double-blind, randomized, placebo-controlled trial, patients aged >12–60 years with ES, oxygen saturation ≤92%, and WHO functional class II/III were randomized 1:1 to metoprolol succinate (starting 25 mg daily, uptitrated to 50 mg daily) or a matching placebo for 16 weeks. The primary endpoint was the change in 6MWD from baseline to week 16. Secondary endpoints included changes in oxygen saturation, NT-proBNP, TAPSE, and clinical composite endpoint.ResultsSixty patients (mean age ~26 Yrs; 58.3% female) were randomized to metoprolol and a matched placebo group (30 per group). In the intention-to-treat analysis, the 6MWD improved by 4.9 m in the metoprolol group and 6.0 m in the placebo group (difference –1.1 m; 95% CI –17.0 to 14.8; p = 0.89). No significant differences occurred in oxygen saturation (–0.06%; 95% Cl -0.62 to 0.72; p = 0.87), TAPSE (0.05 mm; 95% Cl -0.88 to 0.75; p = 0.88), or NT-proBNP (37% increase versus 13% reduction; p = 0.06). The clinical composite occurred in 7/21 (33.3%) metoprolol patients versus 1/23 (4.3%) placebo patients (p = 0.048), driven by worsening heart failure in 5 metoprolol patients.ConclusionsMetoprolol succinate did not improve exercise capacity in ES and was associated with increased clinical worsening. Routine beta-blocker use is not recommended in Eisenmenger syndrome.
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMetoprolol therapy in patients with Eisenmenger Syndrome (MINES) study. A single-center, double-blinded, randomized, placebo-controlled trial
BackgroundBeta-blockers may be useful in the prevention of progressive heart failure and sudden death in Eisenmenger syndrome (ES). The guidelines advise against their use due to concerns over negative inotropic effects despite limited evidence of potential benefits.MethodsIn this single-center, double-blind, randomized, placebo-controlled trial, patients aged >12–60 years with ES, oxygen saturation ≤92%, and WHO functional class II/III were randomized 1:1 to metoprolol succinate (starting 25 mg daily, uptitrated to 50 mg daily) or a matching placebo for 16 weeks. The primary endpoint was the change in 6MWD from baseline to week 16. Secondary endpoints included changes in oxygen saturation, NT-proBNP, TAPSE, and clinical composite endpoint.ResultsSixty patients (mean age ~26 Yrs; 58.3% female) were randomized to metoprolol and a matched placebo group (30 per group). In the intention-to-treat analysis, the 6MWD improved by 4.9 m in the metoprolol group and 6.0 m in the placebo group (difference –1.1 m; 95% CI –17.0 to 14.8; p = 0.89). No significant differences occurred in oxygen saturation (–0.06%; 95% Cl -0.62 to 0.72; p = 0.87), TAPSE (0.05 mm; 95% Cl -0.88 to 0.75; p = 0.88), or NT-proBNP (37% increase versus 13% reduction; p = 0.06). The clinical composite occurred in 7/21 (33.3%) metoprolol patients versus 1/23 (4.3%) placebo patients (p = 0.048), driven by worsening heart failure in 5 metoprolol patients.ConclusionsMetoprolol succinate did not improve exercise capacity in ES and was associated with increased clinical worsening. Routine beta-blocker use is not recommended in Eisenmenger syndrome.
- 20 June 2026
- Published by Elsevier in Tissue and Cell
- Vol. 103, 103714
Comparative phenotypic analysis of primary aortic VSMCs versus TGF - β/PDGF - BB differentiated MSCs in rat
- 20 June 2026
- Published by Elsevier in Tissue and Cell
- Vol. 103, 103714
Comparative phenotypic analysis of primary aortic VSMCs versus TGF - β/PDGF - BB differentiated MSCs in rat
- 21 May 2026
- Published by Springer Nature in Journal of Applied Genetics
- p. 1-14
miRNA–mRNA network analysis reveals novel post-transcriptional regulators and therapeutic targets in coronary artery disease
Coronary artery disease (CAD) remains one of the leading causes of mortality worldwide, driven by complex gene regulatory mechanisms. Non coding RNAs such as microRNAs (miRNAs) act as pivotal regulators of CAD pathogenesis. This study employed a multi-omics in silico approach to uncover microRNA (miRNA)-mediated regulatory networks in CAD. Differentially expressed miRNAs were identified from patient cohorts and mapped to target genes. Overlapping common genes (OCGs) between predicted targets and CAD-associated DEGs were used to construct a regulatory network. Hub miRNAs were prioritized, identifying 20 key regulators, including 11 novel hub-level regulatory candidates not previously prioritized as master regulators in integrated CAD miRNA network analyses. Functional enrichment confirmed the involvement of these OCGs in atherosclerosis and cardiomyopathy. A competing endogenous miRNA-lncRNA network was built to explore multi-layered regulation. Possible drug targets were analyzed to assess therapeutic potential for the results. This integrative pipeline offers insights into miRNA-driven CAD mechanisms and highlights novel biomarkers and targets for clinical implementation. Graphical Abstract The alternative text for this image may have been generated using AI. Integrated network analysis reveals miRNA-mediated regulation and druggable targets in coronary artery disease
- 21 May 2026
- Published by Springer Nature in Journal of Applied Genetics
- p. 1-14
miRNA–mRNA network analysis reveals novel post-transcriptional regulators and therapeutic targets in coronary artery disease
Coronary artery disease (CAD) remains one of the leading causes of mortality worldwide, driven by complex gene regulatory mechanisms. Non coding RNAs such as microRNAs (miRNAs) act as pivotal regulators of CAD pathogenesis. This study employed a multi-omics in silico approach to uncover microRNA (miRNA)-mediated regulatory networks in CAD. Differentially expressed miRNAs were identified from patient cohorts and mapped to target genes. Overlapping common genes (OCGs) between predicted targets and CAD-associated DEGs were used to construct a regulatory network. Hub miRNAs were prioritized, identifying 20 key regulators, including 11 novel hub-level regulatory candidates not previously prioritized as master regulators in integrated CAD miRNA network analyses. Functional enrichment confirmed the involvement of these OCGs in atherosclerosis and cardiomyopathy. A competing endogenous miRNA-lncRNA network was built to explore multi-layered regulation. Possible drug targets were analyzed to assess therapeutic potential for the results. This integrative pipeline offers insights into miRNA-driven CAD mechanisms and highlights novel biomarkers and targets for clinical implementation. Graphical Abstract The alternative text for this image may have been generated using AI. Integrated network analysis reveals miRNA-mediated regulation and druggable targets in coronary artery disease
- Open Access
- 24 March 2026
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 29, 200624
Prognostic significance of carotid intima-media thickness in patients with coronary slow flow: A systematic review and meta-analysis
- 24 March 2026
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 29, 200624
Open AccessPrognostic significance of carotid intima-media thickness in patients with coronary slow flow: A systematic review and meta-analysis
- Open Access
- 30 October 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (1) , 111-114
Unique Coexistence of Dual Left Anterior Descending Artery and Split Right Coronary Artery
We report a case of a 50-year-old male presenting with class III angina on exertion, where an electrocardiogram-gated coronary computed tomography angiography (CCTA) demonstrated the unique coexistence of a type IV dual left anterior descending artery and a split right coronary artery. This case underscores the importance of CCTA in accurately delineating rare coronary artery anatomical variants to avoid both a misdiagnosis and the risk of potential catastrophic outcomes during interventional or surgical procedures.
- 30 October 2025
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 21 (1) , 111-114
Open AccessUnique Coexistence of Dual Left Anterior Descending Artery and Split Right Coronary Artery
We report a case of a 50-year-old male presenting with class III angina on exertion, where an electrocardiogram-gated coronary computed tomography angiography (CCTA) demonstrated the unique coexistence of a type IV dual left anterior descending artery and a split right coronary artery. This case underscores the importance of CCTA in accurately delineating rare coronary artery anatomical variants to avoid both a misdiagnosis and the risk of potential catastrophic outcomes during interventional or surgical procedures.